This valuable study analyzes aging-related chromatin changes through the lens of intra-chromosomal gene correlation length, which is a novel computational metric that captures spatial correlations in ...

New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination deficiency and treatment personalization. At the 2025 ESMO Gynecological ...

NEW ORLEANS—A first-in-class peptide-based PET tracer, 18 F-AlF-NOTA-PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer 18 ...

Introduction: Epidermal growth factor receptor 2 (HER2) and programmed cell death ligand 1 (PD-L1) are pivotal therapeutic targets for advanced gastric cancer (GC). Nevertheless, the correlation ...

Observational studies or clinical trials reporting tissue-based PD-L1 expression by Tumor Proportional Score/Combined Positive Score using immunohistochemistry were included. Clinical trials of BTC ...

Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer. In a study, ...

The study will assess safety, preliminary efficacy, and biomarker correlations, potentially paving a path toward accelerated development. The biomarker-focused trial will target high-risk NSCLC ...

The growing application of immune checkpoint inhibitors (ICIs) in cancer immunotherapy has underscored the critical need for reliable methods to identify patient populations likely to respond to ICI ...

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...

The authors provide useful data to support the existence of a regulatory pathway starting with SPI1-driven ZFP36L1 expression, that goes on to downregulate HDAC3 expression at the transcript level, ...